Table 1. The EGFR and HER2 expression of A431, U343, SKOV3 and SKBR3 cells in four culturing conditions.
| A431 | U343 | SKOV3 | SKBR3 | |||||||||
| EGFR | HER2 | KD, app | EGFR | HER2 | KD, app | EGFR | HER2 | KD, app | EGFR | HER2 | KD, app | |
| Complete medium | 2.1±0.4E6 | 1.5±0.1E5 | 8 nM | 6.4±0.5E5 | 3.1±0.6E4 | 1.4 nM | 3.4±0.6E5 | 2.0±0.3E7 | 0.9 nM | 4.1±0.3E5 | 5.8±0.5E6 | 0.2 nM |
| Serum free medium | 2.2±0.5E6 | 1.7±0.2E5 | 6.7±0.6E5 | 3.5±0.4E4 | 1.9±0.2E5 | 2.1±0.05E7 | 3.5±0.5E5 | 7.2±0.6E6 | ||||
| Gefitinib +complete medium | 2.2±0.3E6 | 2.6±0.5E5 | 6.9±1.0E5 | 2.2±0.3E4 | 3.2±0.6E5 | 2.3±0.1E7 | 4.6±0.6E5 | 6.4±2.6E6 | ||||
| Gefitinib +serum free medium | 1.3±0.2E6 | 2.0±0.5E5 | 5.3±0.1E5 | 2.7±0.3E4 | 2.18E+05E5 | 3.0±0.4E6 | 5.7±0.3E5 | 6.5±0.3E6 | ||||
Estimation of EGFR and HER2 receptors were conducted either manually or by the KEX method using LigandTracer. Estimations of the affinities have been described previously [22]. Data are presented as mean±S.E (n = 2−6). No clear effects of the treatments on the EGFR and HER2 expression is observed in either of the cell lines.